Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer therapy

Off-the-shelf CAR T cells for multiple myeloma

Nature Medicine (2023)Cite this article

Subjects

A study showing feasibility and preliminary efficacy of off-the-shelf CAR T cells represents steady progress on the long road to clinical use.

Nevertheless, generation of autologous CAR T cell products is extremely time consuming and costly, prompting researchers to explore alternative strategies to overcome these limitations. In this issue of Nature Medicine, Mailankody et al.4 report results of part A of the phase 1 UNIVERSAL clinical trial, which evaluated ALLO-715, an allogeneic off-the-shelf anti-BCMA CAR T cell product. The study demonstrated that administering these off-the-shelf CAR T cells is feasible, and that the therapy has clear anti-malignancy activity in multiple myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).

    Article  CAS  Google Scholar 

  2. Martin, T. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO.22.00842 (2022).

    Article  Google Scholar 

  3. Delforge, M. et al. Blood Adv. 6, 1309–1318 (2022).

    Article  CAS  Google Scholar 

  4. Mailankody, S. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02182-7 (2023).

  5. Graham, C. E. et al. Leukemia 35, 3581–3584 (2021).

    Article  CAS  Google Scholar 

  6. Goodman, A. Patients with multiple myeloma may face CAR T-cell shortages. ASCO Post (25 September 2022).

  7. Benjamin, R. et al. Lancet Haematol 9, e833–e843 (2022).

    Article  Google Scholar 

  8. Ottaviano, G. et al. Sci. Transl. Med. 14, eabq3010 (2022).

    Article  CAS  Google Scholar 

  9. Berdeja, J. G. et al. Lancet 398, 314–324 (2021).

    Article  CAS  Google Scholar 

  10. Lonial, S. et al. Cancer 127, 4198–4212 (2021).

    Article  CAS  Google Scholar 

  11. Moreau, P. et al. N. Engl. J. Med. 387, 495–505 (2022).

    Article  CAS  Google Scholar 

  12. Sommer, C. et al. Blood 136, 8 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Jennifer N. Brudno & James N. Kochenderfer

Authors
  1. Jennifer N. Brudno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James N. Kochenderfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer N. Brudno.

Ethics declarations

Competing interests

J.N.B. is on the scientific advisory board for Kyverna Therapeutics, Inc. (unpaid position). J.N.K. receives royalties from Kite (a Gilead company), Celgene/Bristol Myers Squibb and Kyverna Therapeutics, Inc.; and research funding from Kite and Celgene/Bristol Myers Squibb.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brudno, J.N., Kochenderfer, J.N. Off-the-shelf CAR T cells for multiple myeloma. Nat Med (2023). https://doi.org/10.1038/s41591-022-02195-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41591-022-02195-2

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research